Literature DB >> 17251258

Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome.

Andrea Sarkozy1, Tim Boussy, Georgios Kourgiannides, Gian-Battista Chierchia, Sergio Richter, Tom De Potter, Peter Geelen, Francis Wellens, Marieke Dingena Spreeuwenberg, Pedro Brugada.   

Abstract

AIMS: To analyse the follow-up data of implantable cardioverter-defibrillator (ICD) therapy in Brugada syndrome (BS). METHODS AND
RESULTS: We conducted a retrospective, single centre study of 47 patients (mean age: 44.5 +/- 15 years) with BS, who underwent primary prophylactic ICD implantation. All patients had baseline spontaneous (23 patients) or drug-induced (24 patients) coved type I ECG pattern. All patients were judged to be at high risk because of syncope (26 patients) and/or a positive family history of sudden death (26 patients). During a median follow-up of 47.5 months, seven patients had appropriate shocks. The presence of spontaneous type I ECG and non-sustained ventricular tachyarrhythmia in the ICD datalog suggested a trend towards shorter appropriate shock-free survival by Kaplan-Meier analysis (P = 0.037 and P = 0.012, respectively). Seventeen patients received inappropriate shocks (IS); eight patients for sinus tachycardia; six patients for new onset atrial arrhythmias; and five patients for noise oversensing. In multivariable Cox-regression analysis, new onset atrial fibrillation (AF) and less than 50 years of age were independent predictors of significantly shorter IS-free survival (P = 0.04 and P = 0.036, respectively).
CONCLUSION: In high-risk patients with BS, primary prophylactic ICD therapy is an effective treatment. In this, young and otherwise healthy patient population, the IS rate is high.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251258     DOI: 10.1093/eurheartj/ehl450

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  37 in total

1.  DNA fragmentation in leukocytes following subacute low-dose nerve agent exposure.

Authors:  J R Moffett; R A Price; S M Anderson; M L Sipos; A V Moran; F C Tortella; J R Dave
Journal:  Cell Mol Life Sci       Date:  2003-10       Impact factor: 9.261

2.  [The ICD as primary prevention. Rare indications].

Authors:  K Wasmer; J Köbe; C Pott; L Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-06

3.  Risk stratification [corrected] of Brugada syndrome revisited.

Authors:  Eyal Nof; Charles Antzelevitch
Journal:  Isr Med Assoc J       Date:  2008-06       Impact factor: 0.892

4.  [Brugada syndrome].

Authors:  Christian Wolpert; Claudia Herrera-Siklody; Ulli Parade; Christian Strotmann; Norman Rüb
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-12

Review 5.  The Diagnosis, Risk Stratification, and Treatment of Brugada Syndrome.

Authors:  Johannes Steinfurt; Jürgen Biermann; Christoph Bode; Katja E Odening
Journal:  Dtsch Arztebl Int       Date:  2015-06-05       Impact factor: 5.594

Review 6.  The Brugada Syndrome - Diagnosis, Clinical Implications and Risk Stratification.

Authors:  Velislav N Batchvarov
Journal:  Eur Cardiol       Date:  2014-12

7.  Brugada syndrome: Controversies in Risk stratification and Management.

Authors:  Lm Nunn; J Bhar-Amato; Pd Lambiase
Journal:  Indian Pacing Electrophysiol J       Date:  2010-09-05

8.  Prevention of inappropriate ICD shocks in patients with Brugada syndrome.

Authors:  Christian Veltmann; Juergen Kuschyk; Rainer Schimpf; Florian Streitner; Nina Schoene; Martin Borggrefe; Christian Wolpert
Journal:  Clin Res Cardiol       Date:  2009-09-16       Impact factor: 5.460

Review 9.  Channelopathies: Brugada syndrome, long QT syndrome, short QT syndrome, and CPVT.

Authors:  Rainer Schimpf; Christian Veltmann; Christian Wolpert; Martin Borggrefe
Journal:  Herz       Date:  2009-06       Impact factor: 1.443

10.  Sugammadex in a Patient with Brugada Syndrome.

Authors:  Ebru Biricik; Zehra Hatipoğlu; Çağatay Küçükbingöz
Journal:  Turk J Anaesthesiol Reanim       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.